Certara, Inc.

certara.com

What Do They Do?

Builds software and provides scientific and consulting services that help pharmaceutical and biotech companies model how medicines act in the body, analyze drug-development data, and prepare approval filings.

How Do They Make Money?

Customers buy software licenses, cloud subscriptions, maintenance and support, and consulting services. Fees for term licenses, subscriptions, and support are generally due in advance; consulting is billed periodically or at project milestones as work progresses.

FY2025 revenue

Who Are Their Customers?

A global commercial team works with life sciences companies and contract research organizations; academic, government, and regulatory institutions also use its products, while software distributors may serve regions or categories where the company has less sales presence.

Do Revenues Turn Into Profits?

Not on paper. It lost $1.6M in FY2025, but brought in more cash than it spent: $94.6M of free cash flow.

Operating income, FY2025

5% of revenue

▲ Now profitable vs FY2024 (−$1.7M, 0%)

Net income, FY2025

0% of revenue

▼ −87% (Loss) vs FY2024 (−$12.1M, −3%)

Free cash flow, FY2025

23% of revenue

▲ +20% vs FY2024 ($78.8M, 20%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +1%; vs $92.4M in Q2 FY2025
Net income: ▲ +2708% (Loss); vs −$2M in Q2 FY2025

Aug 4, 2026 Reaffirmed 2026 revenue growth guidance The company expects full-year revenue growth of 0% to 4% on a comparable continuing operations basis.
Jun 17, 2026 Announced the chief financial officer’s departure and named an interim successor Faiz Mohammed was appointed interim chief financial officer while the company searches for a successor.
May 11, 2026 Completed sale of the medical writing and related regulatory services business The business was sold to Veristat for cash consideration, with additional escrow and earn-out terms.

Growing. Revenue grew 46% in 4 years, from $286.1M in FY2021 to $418.8M in FY2025, about 10% a year.

Added chemical research software The portfolio includes Chemaxon tools for chemical search, property prediction, and analysis, extending the biosimulation platform into chemical workflows used in drug discovery.

Added generative AI tools Certara.AI and the updated CoAuthor add generative AI to regulatory writing tools and submission software described in the earlier report.

Who Do They Compete With?

Competes with Mathworks, Dassault Systemes, Ansys, Simulations Plus, ICON, Metrum Research, qPharmetra, and Pharmetheus

Comments